Bioxcel Therapeutics Announces Enrollment Of First Patients In U.S. Department Of War-Funded Study Of BXCL501 (Sublingual Dexmedetomidine) For Treatment Of Acute Stress Reactions April 8, 2026 stress ONLY AVAILABLE IN PAID PLANS. Originally reported by menafn. Read more Source: https://menafn.com/1110956920/Bioxcel-Therapeutics-Announces-Enrollment-Of-First-Patients-In-US-Department-Of-War-Funded-Study-Of-BXCL501-Sublingual-Dexmedetomidine-For-Treatment-Of-Acute-Stress-Reactions
